Clinical trial
A Non-interventional Post-marketing Study, Evaluating Seizure Control and Tolerability of Vimpat® as Adjunctive Therapy to One Baseline Antiepileptic Drug in Epilepsy Patients With Partial-onset Seizures With or Without Secondary Generalization in Daily Clinical Practice in Germany
NCT01098162 is registered in ClinicalTrials.gov with UCB Pharma GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Non-interventional Post-marketing Study, Evaluating Seizure Control and Tolerability of Vimpat® as Adjunctive Therapy to One Baseline Antiepileptic Drug in Epilepsy Patients With Partial-onset Seizures With or Without Secondary Generalization in Daily Clinical Practice in Germany
- Lead sponsor
- UCB Pharma GmbH
- Phase
- Observational
- Overall status
- Completed
- Start date
- March 31, 2010
- Completion date
- July 31, 2013
- Enrollment
- 576 (actual)
- Sites
- 113
Conditions
As the registry lists them; a condition with its own page is linked.